| 规格: | 98% |
| 分子量: | 393.5 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
Background:
Cefprozil-d4is intended for use as an internal standard for the quantification of cefprozil by GC- or LC-MS. Cefprozil is an orally bioavailable, second generation, broad-spectrum cephalosporin antibiotic that inhibits the growth of both Gram-positive and Gram-negative bacteria.1,2It inhibits the growth ofE. coli,E. faecalis,E. faecium,N. gonorrhoeae,N. meningitidis,P. mirabilis,S. aureus,S. pyogenes, andS. pneumoniaestrains (MICs = 0.013-25 μg/ml) and clinical isolates of penicillin-susceptible, -intermediate, and -resistantS. pneumoniaeand methicillin-sensitiveS. aureus(MIC90s = 0.12-16 μg/ml).In vivo, cefprozil protects mice challenged withE. coli,S. aureus,S. pyogenes, andP. mirabilisstrains with protective doses (PD50s) ranging from 0.07 to 1.3 mg/kg.1Cefprozil binds to penicillin-binding proteins (PBPs), which disrupts their ability to cross-link peptidoglycan and leads to weakened bacterial cell walls.3Formulations containing cefprozil have been used in the treatment of respiratory tract, skin, and other bacterial infections.
1.Tomatsu, K., Ando, S., Masuyoshi, S., et al.In vitro and in vivo evaluations of BMY-28100, a new oral cephalosporinJ. Antibiot. (Tokyo)40(8)1175-1183(1987) 2.Peric, M., Browne, F.A., Jacobs, M.R., et al.Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: Use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agentsClin. Ther.25(1)169-177(2003) 3.Nagai, K., Davies, T.A., Jacobs, M.R., et al.Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococciAntimicrob. Agents Chemother.46(5)1273-1280(2002)
m.cnreagent.com
